Maze Therapeutics, Inc. (MAZE): Net Income

Annual figures by period end, from SEC filings.

-$131.12M

Year ended 2025-12-31

-$133.59M

Trailing 12 months to 2026-06-30

2024-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$131.12M	n/m	2026-03-25, From 2025-01-01
2024-12-31	$52.23M	n/a	2026-03-25, From 2024-01-01

Net Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Maze Therapeutics, Inc. (MAZE)	2025-12-31	-$131.12M	n/m
Scholar Rock Holding Corp (SRRK)	2025-12-31	-$377.94M	n/m
Allogene Therapeutics, Inc. (ALLO)	2025-12-31	-$190.89M	n/m
Sana Biotechnology, Inc. (SANA)	2025-12-31	-$244.17M	n/m
Scilex Holding Co (SCLX)	2025-12-31	-$374.05M	n/m
C4 Therapeutics, Inc. (CCCC)	2025-12-31	-$104.99M	n/m
Cullinan Therapeutics, Inc. (CGEM)	2025-12-31	-$219.88M	n/m
Kodiak Sciences Inc. (KOD)	2025-12-31	-$229.97M	n/m
Monte Rosa Therapeutics, Inc. (GLUE)	2025-12-31	-$38.63M	n/m

Compare MAZE, SRRK, ALLO, SANA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗